How many drugs treat Peptostreptococcus infection?

Drug Landscape tracks 5 marketed treatments for Peptostreptococcus infection (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/peptostreptococcus-infection.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peptostreptococcus infection — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peptostreptococcus infection (disease) competitive landscape: 5 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

5 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Peptostreptococcus infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Invanz	ERTAPENEM	Merck & Co.	Penem Antibacterial		2001-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Metro I.V. In Plastic Container	METRONIDAZOLE	Baxter	Nitroimidazole Antimicrobial [EPC]		1963-01-01
Ceftriaxon	Ceftriaxon	Centre Hospitalier Universitaire Vaudois		Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A
Metronidazol	Metronidazol	University of Oslo		Thioredoxin reductase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Peptostreptococcus infection
Baxter · 1 drug in Peptostreptococcus infection
Centre Hospitalier Universitaire Vaudois · 1 drug in Peptostreptococcus infection
Generic (originally Roche) · 1 drug in Peptostreptococcus infection
Merck & Co. · 1 drug in Peptostreptococcus infection
University of Oslo · 1 drug in Peptostreptococcus infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Peptostreptococcus infection:

Cite this brief

Drug Landscape (2026). Peptostreptococcus infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/peptostreptococcus-infection. Accessed 2026-06-10.

Peptostreptococcus infection full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing